Patents Assigned to Alynylam Pharmaceuticals, Inc.
  • Compositions and methods for inhibiting expression of the ALAS1 gene
    Patent number: 10125364
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: November 13, 2018
    Assignees: ALYNYLAM PHARMACEUTICALS, INC., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • Method and medicament for inhibiting the expression of a given gene
    Patent number: 9902954
    Abstract: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: February 27, 2018
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Roland Kreutzer, Stefan Limmer
  • Compositions and methods for increasing erythropoietin (EPO) production
    Patent number: 9193973
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Alynylam Pharmaceuticals, Inc., Dana-Farber Cancer Institute
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Compositions and methods for inhibiting expression of factor V
    Patent number: 8658782
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: February 25, 2014
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Compositions and methods for inhibiting expression of huntingtin gene
    Patent number: 8314075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 20, 2012
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot